Closer to ideal insulin action: Ultra fast acting insulins

Panminerva Medica

Volumn 55, Issue 3, 2013, Pages 269-275

  Cengiz, E ^a  

^a 333 Cedar St LMP 3103E   (United States)

Author keywords

Diabetes mellitus; Hyperglycemia; Insulin; Pancreas.

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; INSULIN;

ANIMAL; ARTICLE; BLOOD; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; DRUG DESIGN; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTES; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 84891791640     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-6. (Pubitemid 29418246)
2. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402. (Pubitemid 24064246)
3. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858-62. (Pubitemid 33716491)
4. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(lc). Diabetes Care 2003;26:881-5. (Pubitemid 36929359)
5. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991;72:27782.
6. Swan KL, Weinzimer SA, Dziura JD, Steil GM, Voskanyan GR, Steffen AT et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008;31:44-6.
7. Steil GM, Rebrin K, Darwin C, Hariri F, Saad ME Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344-50. (Pubitemid 44923591)
8. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934-9.
9. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabetic medicine: A journal of the British Diabetic Association 1996;13:625-9.
10. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999;22:801-5. (Pubitemid 29220783)
11. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes, Obesity & Metabolism 2009;11:5-19.
12. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003;26:2027-31. (Pubitemid 41184246)
13. Yamada S. Insulin glulisine in the management of diabetes. Diabetes, metabolic syndrome and obesity: targets and therapy 2009;2:111-5.
14. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clinical Pharmacokinetics 2008;47:720.
15. Gough SC. A review of human and analogue insulin trials. Diabetes Research and Clinical Practice 2007;77:1-15. (Pubitemid 46590471)
16. Luijf YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010;33:2152-5.
17. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clinical Medicine & Research 2008;6:54-67.
18. Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care 2012;35:690-2.
19. Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010;33:100912.
20. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114:230-41. (Pubitemid 44291844)
21. Hechter O. Reconstitution of the dermal barrier to fluid diffusion following administration of hyaluronidase. Proc Soc Exp Biol Med 1948;67:343.
22. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-40. (Pubitemid 47249140)
23. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther 2011;13:1039-45.
24. Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011;34:6668.
25. Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care 2013;36:273-5.
26. Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharmaceutical research 2011;28:107-16.
27. Gupta J, Feiner EI, Prausnitz MR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther 2011; 13:451-6.
28. Norman JJ, Brown MR, Raviele NA, Prausnitz MR, Feiner el. faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatric Diabetes 2013;14:459-65.
29. Nordquist L, Roxhed N, Griss P, Stemme G. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. Pharmaceutical Research 2007;24:1381-8. (Pubitemid 46870597)
30. Roxhed N, Samel B, Nordquist L, Griss P, Stemme G. Painless drug delivery through microneedle-based transdermal patches featuring active infusion. IEEE transactions on bio-medical engineering 2008;55:1063-71. (Pubitemid 351301214)
31. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care 2011;34:1804-8.
32. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effeet of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994;37:377-80. (Pubitemid 24113569)
33. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 1982;5:77-91. (Pubitemid 12132223)
34. Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatric Diabetes 2013;14:16873.
35. Cengiz E WA, Sherr J, Tichy E, Martin M, Carria L, Tamborlane W. Acceleration of Insulin Action by Infusion Site Warming. Diabetes, American Diabetes Association 72nd Scientific Session Abstract 2012;61:225.
36. American Diabetes Association [Homepage], [cited 2013 September]. Available at: http://www.diabetes.org/diabetes-basics/diabetes-statistics/
37. Pfutzner A, Mann AE, Steiner SS. Technosphere/Insulin-a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002;4:589-94. (Pubitemid 35283321)
38. Eldor R, Arbit E, Coreos A, Kidron M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: A pilot study. PloS one 2013;8:e59524.
39. Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol 2009;3:568-84.
40. Clinical trials.gov Evaluation of Accu-Chek DiaPort, A Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes [Internet],[cited 2013 September], Available at: http://clinicaltrials.gov/show/ NCT01483352
41. Liebl A, Hoogma R, Renard E, Geelhoed-Duijvestijn PH, Klein E, Diglas J et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab 2009;11:1001-8.
42. Liebl A GB, Kiehling C, Rieger C, Patte C, Frei T. Evaluation of the New Accu-Check Diaport, a Port System for Continuous Intraperitoneal Infusion in Patients with Type 1 Diabetes. Diabetes, American Diabetes Association 73rd Scientific Session Abstract 2013;62:247-8.
43. Adocia [Homepage], [cited 2013 September]. Available at: http:// www.adocia.com/Les-reponses-d-Adocia,en,44.html
44. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008;51:1602-6.
45. Heinemann L, Hompesch M, Flacke F, Simms P, Pohl R, Albus K et al. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol 2011;5:681-6.
46. Heinemann L, Nosek L, FIacke F, AIbus K, Krasner A, Pichotta P et al. U-100, pH-Neutral formulation of VIAject((R)): faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab 2012;14:222-7.
47. Pohl R, Hauser R, Li M, De Souza E, Feldstein R, Seibert R et al. Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking. J Diabetes Sci Technol 2012;6:755-63.
48. Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, De Souza E. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol 2012;6:786-96.
49. Clinical trials.gov, A Study Evaluating Safety and Efficacy ofBIOD-123 Compared to Insulin Lispro (Humalog®), [cited 2013 September]. Available at: http://clinicaltrials.gov/ct2/show/
50. NCTO1686620?term=biodel&rank=2
51. USPTO PATENT FULL TEXT AND IMAGE DATABASE. Sung et al. Pharmaceutical composition of nanoparticles, [cited 2013 September]. Available at: http://patft.uspto.gov/netacgi/nph-Parse r?Sect 1 =PT02&Sect2=HIT0FF&u= %2Fnetahtml%2FPT0%2F search-adv.htm&r= 17&f=G&l=50&d=PTXT&p= 1 &p= 1 &S 1 =( ((Aspart+AND+diabetes)+AND+insulin)+AND+novo)&OS= Asp art+and+diabetes+and+insulin+and+novo&RS=(((Aspart+AND +diabetes)+AND+insulin)+AND+novo)